
NMRA Stock Forecast & Price Target
NMRA Analyst Ratings
Bulls say
Neumora Therapeutics is a clinical-stage biopharmaceutical company with a promising pipeline of seven neuroscience programs targeting novel mechanisms of action for a broad range of neuropsychiatric disorders and neurodegenerative diseases. Recent data from their Phase 2 trial for their lead program NMRA-215, a NLRP3 inhibitor, showed potential for use in switch and maintenance settings. Their second program, NMRA-511, a V1aR antagonist for Alzheimer's Disease Agitation, is expected to enter Phase 2 in 1Q27, with encouraging data in the pre-specified NPI-AA ≥4 population suggesting a differentiated safety profile. The company has a strong cash runway into 3Q27 and multiple near-term catalysts, making it an attractive investment opportunity.
Bears say
Neumora Therapeutics is leveraging a precision-medicine approach for CNS diseases, focusing on MDD, BPD, and AD agitation. Despite having seven clinical and preclinical programs in its pipeline, a negative outlook is maintained due to previous failed trials and the limited value currently ascribed to its most advanced product candidate, navacaprant. The upcoming pivotal readout in 2Q26 may bring a momentary boost to the company's valuation, but its long-term success and revenue potential remain uncertain.
This aggregate rating is based on analysts' research of Neumora Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
NMRA Analyst Forecast & Price Prediction
Start investing in NMRA
Order type
Buy in
Order amount
Est. shares
0 shares